These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26142890)

  • 21. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
    Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
    Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
    Skovgaard R; Jon Ploug U; Hunt B; Valentine WJ
    Clin Ther; 2015 Aug; 37(8):1677-88. PubMed ID: 26186809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
    Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
    Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system.
    Pantalone KM; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Zimmerman RS
    BMJ Open Diabetes Res Care; 2015; 3(1):e000093. PubMed ID: 26217493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Academic abilities and glycaemic control in children and young people with Type 1 diabetes mellitus.
    Semenkovich K; Patel PP; Pollock AB; Beach KA; Nelson S; Masterson JJ; Hershey T; Arbeláez AM
    Diabet Med; 2016 May; 33(5):668-73. PubMed ID: 26173465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.
    Prasad-Reddy L; Isaacs D
    Drugs Context; 2015; 4():212283. PubMed ID: 26213556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of all-cause and cardiovascular disease mortality in type 2 diabetes: Diabetes Heart Study.
    Raffield LM; Hsu FC; Cox AJ; Carr JJ; Freedman BI; Bowden DW
    Diabetol Metab Syndr; 2015; 7():58. PubMed ID: 26146522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
    Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
    Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Patients with Type 2 Diabetes.
    Nicolucci A; Cercone S; Chiriatti A; Muscas F; Gensini G
    Diabetes Technol Ther; 2015 Aug; 17(8):563-70. PubMed ID: 26154338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of basal insulins.
    Mannucci E; Giannini S; Dicembrini I
    Drug Healthc Patient Saf; 2015; 7():113-20. PubMed ID: 26203281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous glucose monitoring and hypoglycemia unawareness in type 1 diabetes: a pilot study.
    Zalzali M; Houdelet-Guerinot V; Socquard E; Thierry A; Delemer B; Lukas-Croisier C
    Minerva Endocrinol; 2017 Sep; 42(3):195-202. PubMed ID: 26159765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
    Vlasakakis G; Johnson SL; Lin J; Yao X; Gruenloh CJ; Chism JP; Nunez DJ
    Adv Ther; 2015 Jul; 32(7):650-61. PubMed ID: 26160357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
    McCoy RG; Zhang Y; Herrin J; Denton BT; Mason JE; Montori VM; Smith SA; Shah ND
    Am J Manag Care; 2015 May; 21(5):e288-96. PubMed ID: 26167776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes.
    Polonsky WH; Fisher L; Hessler D; Edelman SV
    Diabetes Technol Ther; 2015 Nov; 17(11):773-9. PubMed ID: 26167948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.
    Penfornis A; Fiquet B; Blicklé JF; Dejager S
    Diabetes Metab Syndr Obes; 2015; 8():303-13. PubMed ID: 26170705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of acute caffeine supplementation on reducing exercise-associated hypoglycaemia in individuals with Type 1 diabetes mellitus.
    Zaharieva DP; Miadovnik LA; Rowan CP; Gumieniak RJ; Jamnik VK; Riddell MC
    Diabet Med; 2016 Apr; 33(4):488-96. PubMed ID: 26173655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
    Araki E; Inagaki N; Tanizawa Y; Oura T; Takeuchi M; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):994-1002. PubMed ID: 26179754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantile Regression Modeling of Latent Trajectory Features with Longitudinal Data.
    Ma H; Peng L; Fu H
    J Appl Stat; 2019; 46(16):2884-2904. PubMed ID: 32132765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges.
    Lin Y; Wessel J
    Curr Diab Rep; 2019 Feb; 19(4):16. PubMed ID: 30806820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.